Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

AMRO.  We initiated a study called FOCUS FH late last year designed to support the addition of severe heterozygous FH to the label for KYNAMRO."

"While KYNAMRO is our flagship drug, our pipeline goes well beyond KYNAMRO.  With drugs in numerous therapeutic areas, we have many opportunities for both short- and long-term revenue growth.  We have several drugs that may provide substantial commercial opportunities with product launches that could occur within the next five years.  These include our TTR amyloidosis and Spinal Muscular Atrophy drugs from our severe and rare disease franchise, which, due to the significant unmet medical need and orphan patient populations, could warrant an accelerated path to market.  We expect that, if successful, they could be available for patients within the next five years.  In addition, we are implementing a staged development path for our triglyceride-lowering drug, ISIS-APOCIIIRx, that could bring this important new medicine to the market sooner for patients with extremely high and poorly controlled triglycerides who, as a result, are at severe risk of disease," continued Ms. Parshall.

"In addition to the potential near-term product opportunities in our pipeline, we have several drugs that could represent significant licensing opportunities in the next year or two.  With robust Phase 2 data packages, we may be able to command lucrative licensing terms for these drugs.  Among these near-term licensing opportunities is our anticoagulant drug targeting Factor XI and our CRP drug from our cardiovascular franchise.  Both of these drugs have the potential to treat numerous diseases with significant market potential.  In addition, we have several drugs from our metabolic franchise that could complete Phase 2 studies in the next two years and could also provide significant licensing opportunities.  These drugs represent novel approaches to the treatment of type 2 diabetes
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
3. Halozyme Reports First Quarter 2012 Financial Results
4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. IRIDEX Reports 2012 First Quarter Results
7. Cambrex Reports First Quarter 2012 Results
8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
11. Neuland Labs Reports Financial Results For Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... , April 21, 2015  The American ... U.S. Food and Drug Administration that the agency,s ... for the last 25 years to protect the ... homeopathic medicines. AAHP, the industry,s trade association, was ... of homeopathic medicines to engage in productive discussions ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... of amendments to its Clinical Trial Authorizations (CTAs) filed ... Regulatory Agency (MHRA) and Germany,s ... (BfArM) for the expansion of the Company,s global Phase ... hepatocellular carcinoma (primary liver cancer, or HCC), to include ...
Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Society for,Medical Oncology (ESMO) Conference, which is currently ... in two oral and,poster presentations on Sunday, July ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
(Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
(Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
(Date:4/21/2015)... 21, 2015 Optimity Advisors ( ... advisory firm that helps clients in complex industries ... that the Association of Community Affiliated Plans ... ACAP represents 58 local, not-for-profit, community-affiliated Safety Net ... million people primarily enrolled in public or state-sponsored ...
(Date:4/21/2015)... When a bandage sticks to an injury site ... solve this problem two inventors from Festus, Mo., designed ... helps a cut, burn, abrasion or wound heal more ... The bandage is easy to use, versatile and producible ... to the St. Louis office of InventHelp. It is ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
... develop certain hereditary cancers develop them at earlier ages than ... CANCER , a peer-reviewed journal of the American Cancer Society, ... of cancer diagnosis to determine when to provide counseling, screening, ... the BRCA genes have a high risk of developing breast ...
... , SATURDAY, Sept. 10 (HealthDay News) -- It,s important for ... their children to do their homework, a new study suggests. ... toward homework improves if parents take a positive, supportive attitude ... the assignment or getting a higher grade. The study ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... Administration advisers recommended Friday that osteoporosis drugs such as ... clarifying how long a patient should take a drug ... drugs, known as bisphosphonates, are taken to prevent fractures ...
... Preliminary research on Fusarium , a group of ... shows how these microbes travel through the air. ... research, there will be a better understanding about crop ... are steering their efforts towards a new aerobiological modeling ...
... A new study finds that lung cancer patients ... percentage of uninsured and Medicaid-insured patients, so-called "high ... undergo surgery that was intended to cure the ... burden facilities. This difference persisted even after controlling ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third ... inherited metabolic disorder, a new study finds. This ... produced naturally from many foods -- that has a foul, ... a disease that impairs the ability of an enzyme to ...
Cached Medicine News:Health News:Women who inherit BRCA gene mutations develop cancer earlier than their ancestors 2Health News:Parents' Positive Attitude Can Help Kids Get Homework Done 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 3Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2
... Nidek GYC-1000 delivers a solid-state ... of energy and plugs into ... compact design and extreme portability, ... with the Nidek Phaco Emulsification ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: